Predictive and progonstic biomarkers of nivolumab and pembrolizumab treatment in Renal cell and urothelial carcinoma
Not Applicable
Recruiting
- Conditions
- Renal cell cercinoma urothelial carcinoma
- Registration Number
- JPRN-UMIN000025086
- Lead Sponsor
- Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are pregnant or have past history of allergy to immune checkpoint inhibitorsr will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference of progression-free survival (PFS) according to serumchemoline levels and T cell receptor (TCR) repertoire
- Secondary Outcome Measures
Name Time Method The relationship between survivals and , regulatory T cells, MDSC, or other chemokines